PT - JOURNAL ARTICLE AU - MOONSIK KIM AU - JIHWAN YOO AU - JONG HEE CHANG AU - SE HOON KIM TI - Association of <em>MGMT</em> Gene Promoter Methylation With Clinicopathological Parameters in Patients With Wild-type <em>IDH</em> Glioblastoma AID - 10.21873/anticanres.15490 DP - 2022 Jan 01 TA - Anticancer Research PG - 335--341 VI - 42 IP - 1 4099 - http://ar.iiarjournals.org/content/42/1/335.short 4100 - http://ar.iiarjournals.org/content/42/1/335.full SO - Anticancer Res2022 Jan 01; 42 AB - Background: The methylation status of the O6-methylguanine-DNA methyltransferase (MGMT) promoter plays a key role in response to temozolomide chemotherapy and disease prognosis in patients with wild-type isocitrate dehydrogenase (IDH) glioblastoma (GBM). Patients and Methods: The MGMT promoter methylation status and its association with clinicopathological parameters were retrospectively analysed in a cohort of 316 patients with GBM with wild-type IDH. Results: MGMT methylation was significantly associated with ATRX chromatin remodeler (ATRX) loss and completion of the standard Stupp protocol. The median durations of overall and progression-free survival for the unmethylated, low-methylated (10-39%), and hypermethylated (≥40%) groups were 15, 23, and 30 months and 11, 18, and 21 months, respectively. However, the improvement in the survival of the hypermethylated group was not statistically significant. Conclusion: We suggest a possible association between MGMT methylation status and ATRX mutations in GBM with wild-type IDH.